News Kyowa Hakko Kirin signs AI drug R&D deal with InveniAI Artificial intelligence and machine learning company InveniAI has joined with Kyowa Hakko Kirin to harness the power of technology for drug discovery.
News Kyowa Kirin to expand UK headquarters despite Brexit Other Japanese firms could scale back UK investment.
News J&J scores EU approval for Tecvayli combo in second line Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.